Monday, 24 August 2026European Markets
ExploreSearch
ViaNews EU
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 17, 2026

Basilea erzielt starke Ergebnisse im Geschäftsjahr 2025 und übertrifft Umsatz- und Betriebsgewinn-Guidance

View original at globenewswire.com
Basilea erzielt starke Ergebnisse im Geschäftsjahr 2025 und übertrifft Umsatz- und Betriebsgewinn-Guidance 15 % Anstieg der Lizenzeinnahmen 11 % Anstieg der GesamtumsätzeNettoliquidität verdreifacht Phase-3-Programm mit Fosmanogepix verläuft wie geplantGesamtumsatz und Betriebsgewinn 2026: zweistelliges Wachstum erwart…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Cumulative positive cash flows of approximately CHF 600 million are expected from Cresemba and Zevtera over the next five-year period

    80% confidence

  • Cresemba generic competition could impact US market from Q4 2027 and European market from H2 2028

    80% confidence

  • Zevtera is expected to gain increasing momentum in the USA from Q2 2026

    80% confidence

  • Potential additional non-dilutive R&D funding of approximately USD 330 million from existing BARDA contracts may be allocated in further tranches

    80% confidence

  • Royalty revenues expected to rise to approximately CHF 120 million and milestone payments to CHF ~35 million in FY2026

    80% confidence

  • FY2026 total revenue is expected to increase by approximately 10%, R&D expenses by approximately 20%, and operating profit by approximately 20%

    80% confidence

  • Basilea reduced the nominal value of outstanding convertible bonds by approximately 22% to CHF 76 million and increased cash position to CHF 162 million in 2025

    80% confidence

  • Phase-3 studies for Fosmanogepix are on track for a data readout in early 2028

    80% confidence

  • Basilea aims to have four drugs on the market by 2030 as well as a broadly positioned R&D pipeline

    80% confidence

  • Since early 2022, Basilea has reduced its financial debt by approximately CHF 145 million

    80% confidence

  • Fosmanogepix and Ceftibuten-Ledaborbactam have potential to double today's in-market revenues by 2030

    80% confidence

  • Basilea has developed into a profitable company with continuously double-digit growth in in-market revenues of products and a leading R&D pipeline in its focus area

    80% confidence

  • Cresemba and Zevtera-based revenues expected to reach approximately CHF 200 million in FY2026

    80% confidence

Cited in these Via News reports